<DOC>
	<DOCNO>NCT03009981</DOCNO>
	<brief_summary>This randomize , open-label , three-arm , phase 3 study men biochemically recurrent prostate cancer PSA double time ≤ 9 month time study entry .</brief_summary>
	<brief_title>A Study Androgen Annihilation High-Risk Biochemically Relapsed Prostate Cancer</brief_title>
	<detailed_description>Patients stratify PSA double time ( &lt; 3 month vs. 3-9 month ) randomize 1:1:1 fashion one three treatment arm : ( 1 ) Control arm consist degarelix monotherapy , ( 2 ) Experimental arm consist apalutamide combination degarelix , ( 3 ) Experimental arm consist apalutamide , abiraterone acetate + prednisone , degarelix . Patients treat maximum duration 52 week enter follow phase time PSA progression , development metastasis , patient withdrawal study , whichever occur first . Patients PSA progression follow long term development castration resistance , first metastasis , death . The primary endpoint study PSA progression-free survival intent-to-treat patient population . PSA progression 52-week treatment period define rise PSA confirm repeat measurement , least 25 % 2 ng/mL nadir baseline , whichever low . PSA progression follow define PSA &gt; 0.2 ng/mL confirm repeat measurement least 2 week later . Secondary study endpoint include PSA progression-free survival testosterone-evaluable population , 36-month PSA progression-free survival rate intent-to-treat testosterone-evaluable population , time testosterone recovery , time castration resistance , metastasis-free survival , quality life , safety . Each experimental arm compare control arm pair-wise fashion . The study power detect difference primary secondary endpoint two experimental arm .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Histologically confirm prostate adenocarcinoma Prior radical prostatectomy Biochemically recurrent prostate cancer PSA double time ≤ 9 month time study entry . Calculation PSA double time include use available PSA value obtain within past 12 month prior randomization , minimum 3 value separate least 2 week apart . PSA value obtain prior localize therapy exclude . PSA double time estimate use Memorial Sloan Kettering Cancer Center online calculator ( http : //www.mskcc.org/nomograms/prostate/psadoublingtime ) Prior adjuvant salvage radiation candidate radiation base upon clinical assessment disease characteristic patient comorbidities . Screening PSA &gt; 0.5 ng/mL No definitive evidence metastasis screen CT MRI abdomen/pelvis radionuclide whole body bone scan per judgment investigator . Abdominal and/or pelvic lymph node measure 2 cm less short axis diameter allow . Lesions identify image modality ( e.g . PSMA choline PET ) visualize CT and/or MRI radionuclide bone scan allow . Equivocal lesion bone scan follow additional imaging clinically indicate . Screening serum testosterone &gt; 150 ng/dL Eastern Cooperative Oncology Group ( ECOG ) Performance Status grade 0 1 Age ≥ 18 year Medications know low seizure threshold ( see Appendix 1 ) must discontinue substitute least 4 week prior study entry . Agrees use condom ( even men vasectomy ) another effective method birth control sex woman childbearing potential agrees use condom sex woman pregnant study drug 3 month follow last dose study drug . Must also agree donate sperm study 3 month receive last dose study drug . Adequate organ function define follow laboratory value screen : Serum aspartate transaminase ( AST ; serum glutamic oxaloacetic transaminase [ SGOT ] ) serum alanine transaminase ( ALT ; serum glutamic pyruvic transaminase [ SGPT ] ) &lt; 2.5 x upper limit normal ( ULN ) Total serum bilirubin ≤1.5 x ULN . In subject Gilbert 's syndrome , total bilirubin &gt; 1.5 × ULN , measure direct indirect bilirubin direct bilirubin ≤1.5 × ULN , subject may eligible ) Serum potassium ≥ 3.5 mmol/L . Supplementation rescreening allow . Estimated GFR &gt; 45 ml/min use CockroftGault equation Platelets ≥ 100,000/microliter independent transfusion and/or growth factor within 3 month prior randomization Hemoglobin ≥ 9.0 g/dL independent transfusion and/or growth factor within 3 month prior randomization Serum albumin ≥ 3.0 g/dL Prior androgen deprivation therapy and/or first generation antiandrogen ( e.g . bicalutamide , nilutamide , flutamide ) biochemically recurrent prostate cancer . Prior ADT and/or first generation antiandrogen ( neo ) adjuvant and/or salvage setting , , and/or follow radiation surgery allow provide last effective dose ADT and/or firstgeneration antiandrogen &gt; 9 month prior date randomization total duration prior therapy ≤ 36 month . Prior treatment CYP17 inhibitor ( e.g . ketoconazole , abiraterone acetate , galeterone ) second generation androgen receptor antagonist include apalutamide enzalutamide Prior chemotherapy prostate cancer except administer neoadjuvant adjuvant setting Use 5alpha reductase inhibitor within 42 day prior randomization Use investigational agent within 28 day prior randomization Use prohibit medication within 7 day prior cycle 1 day 1 study ( Arms B C ) ( see Appendix 1 list prohibit medication ) Prior bilateral orchiectomy Seizure know condition may predispose seizure ( e.g . prior stroke within 1year randomization , brain arteriovenous malformation , Schwannoma , meningioma , benign CNS meningeal disease may require treatment surgery radiation therapy ) Uncontrolled hypertension Gastrointestinal disorder affect absorption ability swallow tablet Baseline severe hepatic impairment ( ChildPugh Class B &amp; C ) Intercurrent illness control active infection , psychiatric illness/social situation would limit compliance study requirement Any chronic medical condition require high dose corticosteroid equivalent 5 mg prednisone/prednisolone daily</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PSA</keyword>
	<keyword>Degarelix</keyword>
	<keyword>Apalutamide</keyword>
	<keyword>Abiraterone Acetate</keyword>
	<keyword>Radical Prostatectomy</keyword>
</DOC>